Company Profiles

driven by the PitchBook Platform

Numerate

Description

Developer of a drug engineering platform. The company offers a platform which is used to design and develop small molecule therapeutics over a range of therapeutic areas, including cardiovascular, metabolic,and neurodegenerative diseases.

2007

Founded

PRIVATE

Status

11-50

Employees

Series A

Latest Deal Type

$8.24M

Latest Deal Amount

$17.5M

Total Amount Raised

Description

Developer of a drug engineering platform. The company offers a platform which is used to design and develop small molecule therapeutics over a range of therapeutic areas, including cardiovascular, metabolic,and neurodegenerative diseases.

Website:

www.numerate.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

1150 Bayhill Drive Suite 203 San Bruno, CA 94066United States +1 (650) 472-0632
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Numerate's full profile, request a free trial.

Numerate Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Numerate Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Numerate Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Atlas VentureVenture CapitalMinority000 0000000 0000
Foundation CapitalVenture CapitalMinority000 0000000 0000
Lanza Tech VenturesVenture CapitalMinority000 0000000 0000
Leader VenturesLender/Debt ProviderMinority000 0000000 0000
Lilly VenturesCorporate Venture CapitalMinority000 0000000 0000
Atlas Venture Venture Capital
Foundation Capital Venture Capital
Lanza Tech Ventures Venture Capital
Leader Ventures Lender/Debt Provider
Lilly Ventures Corporate Venture Capital

Numerate Executive Team (9)

NameTitleBoard
Seat
Contact
Info
Guido LanzaPresident, Chief Executive Officer & Board Member
John Griffin Ph.DChief Scientific Officer
Brandon Allgood Ph.DChief Technology Officer & Co-Founder
E. Lacey GordonController
Brian RaimundoDirector, Medicinal Chemistry
Guido Lanza President, Chief Executive Officer & Board Member
John Griffin Ph.D Chief Scientific Officer
Brandon Allgood Ph.D Chief Technology Officer & Co-Founder
E. Lacey Gordon Controller
Brian Raimundo Director, Medicinal Chemistry

Numerate Board Members (4)

NameRepresentingRoleSinceContact
Info
Bruce Booth Ph.DAtlas VenturePartner000 0000
Guido LanzaNumeratePresident, Chief Executive Officer & Board Member000 0000
Lucio Lanza Ph.DNumerateAdvisor & Board Member000 0000
Steven Hall Ph.DLilly VenturesGeneral Partner000 0000
Bruce Booth Ph.D Partner Atlas Venture
Guido Lanza President, Chief Executive Officer & Board Member Numerate
Lucio Lanza Ph.D Advisor & Board Member Numerate
Steven Hall Ph.D General Partner Lilly Ventures
Request full access to PitchBook